Today: 17 May 2026
Morgan Stanley stock rises as Michael Grimes returns — and traders brace for jobs, CPI
9 February 2026
2 mins read

Morgan Stanley stock rises as Michael Grimes returns — and traders brace for jobs, CPI

New York, February 9, 2026, 14:15 ET — Regular session

  • Morgan Stanley shares climb roughly 2% in afternoon trading
  • The bank has turned to veteran dealmaker Michael Grimes, naming him head of investment banking.
  • IPO prospects and a fresh round of U.S. data this week still have traders weighing rate moves and deal activity.

Shares of Morgan Stanley climbed Monday, with the stock gaining $3.30 to trade at $183.26, up roughly 1.8% by mid-afternoon. Investors responded to the bank’s move to bring back Michael Grimes, a seasoned dealmaker, to head up investment banking.

This hire is key—the focus for major U.S. banks now turns to chasing bigger fee pools. Goldman Sachs analysts are betting that U.S. IPO proceeds could hit $160 billion in 2026, four times what they are now, if dealmaking picks up. Still, they warn that volatility and valuation risks could easily disrupt that forecast.

Stocks calmed down a bit after software names took a hit thanks to last week’s AI selloff, and with the Fed looming, traders are back on edge. “It’s an eye-popping number, $650 billion,” Anna Rathbun, founder and CEO of Grenadilla Advisory, said of Big Tech’s AI spending plans. On the near-term radar: January’s delayed nonfarm payrolls lands Wednesday, January CPI is out Friday, and Nvidia delivers results later this month. Reuters

According to the memo, Grimes, who just wrapped up a stint as senior adviser at the U.S. Commerce Department, spent over 30 years at Morgan Stanley. “Michael will continue to manage and build relationships with many of our most important global corporate, venture, private equity and sovereign clients,” the note said. He’s set up shop in Menlo Park, California. Grimes brings a history of high-profile IPOs—Meta, Uber—and has teamed with Elon Musk on both Tesla’s market debut and that $44 billion Twitter deal. Reuters previously named Morgan Stanley as a frontrunner for a possible SpaceX role. Investing.com South Africa

Morgan Stanley’s move speaks for itself: they’re bringing in a familiar tech dealmaker just as companies edge back toward public offerings. Investment banking fees swing with the deal calendar — that’s just how it goes — and the market hasn’t hesitated to factor those ups and downs straight into the stock.

In recent years, the bank has pushed further into its wealth business to help steady its results. Still, MS shares usually move with two familiar drivers: how much risk investors are willing to take, and the volume of deal activity—just like its rivals.

The action Monday lined up with the broader trend. As beaten-down tech names rebounded and investors rotated through sectors, broker-dealers caught a lift—even absent any fresh earnings news. More trading from clients, plus a little extra risk appetite from corporate boards, did the trick.

The flip side is just as clear. Should markets lurch back into volatility, or if this week’s data jolts rate expectations, private firms might simply pause, leaving M&A to drift into another “wait and see” stretch. Advisory and underwriting fees would take the hit—precisely when Wall Street’s still spending on bankers and tech.

Investors are scanning for any hints that the IPO window is cracking open, and staying alert to fresh signs the economy may be slowing enough to bring rate cuts forward. They’re also eyeing risk assets to see if last week’s jolt turns into something bigger.

Up next for Morgan Stanley: wealth management chief Jed Finn has a spot at the UBS Financial Services Conference on Tuesday. He’s slated to speak February 10 at 3:30 p.m. ET, and the bank will share a webcast.

Stock Market Today

  • Aquestive Therapeutics Reports Strong Q1 Results, Analysts Maintain 2026 Forecasts
    May 16, 2026, 8:17 PM EDT. Aquestive Therapeutics (NASDAQ:AQST) posted strong first-quarter results with revenues of $14 million, surpassing analyst expectations by 33%, and smaller-than-expected losses of $0.07 per share. Despite the upbeat quarter, analysts forecast a 3.6% revenue decline in 2026 to $48.4 million and a 15% decrease in losses to $0.47 per share. The consensus price target remains steady at $8.89, suggesting the stock is trading in line with expectations amid continuing losses. Revenue growth is expected to slow significantly compared to the past five years, lagging behind an 8% annual growth forecast for the wider industry. Investors face mixed views on valuation, with targets ranging from $6.00 to $11.00 per share.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms
Previous Story

AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms

Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal
Next Story

Why Constellation Energy (CEG) stock is up today: new 380‑MW Texas data center deal

Go toTop